Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | CHEK2 |
| Variant | W93Gfs*17 |
| Impact List | frameshift |
| Protein Effect | loss of function - predicted |
| Gene Variant Descriptions | CHEK2 W93Gfs*17 indicates a shift in the reading frame starting at amino acid 93 and terminating 17 residues downstream causing a premature truncation of the 543 amino acid Chek2 protein (UniProt.org). W93Gfs*17 results in decreased Kap1 phosphorylation in culture (PMID: 34903604), and therefore, is predicted to lead to a loss of Chek2 protein function. |
| Associated Drug Resistance | |
| Category Variants Paths |
CHEK2 mutant CHEK2 inact mut CHEK2 W93Gfs*17 |
| Transcript | NM_007194.4 |
| gDNA | chr22:g.28734445delA |
| cDNA | c.277delT |
| Protein | p.W93Gfs*17 |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_145862.2 | chr22:g.28734445delA | c.277delT | p.W93Gfs*17 | RefSeq | GRCh38/hg38 |
| NM_007194.3 | chr22:g.28734445delA | c.277delT | p.W93Gfs*17 | RefSeq | GRCh38/hg38 |
| NM_007194 | chr22:g.28734445delA | c.277delT | p.W93Gfs*17 | RefSeq | GRCh38/hg38 |
| XM_011529843 | chr22:g.28734445delA | c.277delT | p.W93Gfs*17 | RefSeq | GRCh38/hg38 |
| XM_047441105.1 | chr22:g.28734445_28734446insTTGGGCC | c.276_277insGGCCCAA | p.W93Gfs*17 | RefSeq | GRCh38/hg38 |
| NM_001005735.1 | chr22:g.28734445_28734446insTTGGGCC | c.276_277insGGCCCAA | p.W93Gfs*17 | RefSeq | GRCh38/hg38 |
| NM_001005735.2 | chr22:g.28734445_28734446insTTGGGCC | c.276_277insGGCCCAA | p.W93Gfs*17 | RefSeq | GRCh38/hg38 |
| XM_011529841 | chr22:g.28734446_28734447insCGGGCCG | c.276_277insGGCCCGC | p.W93Gfs*17 | RefSeq | GRCh38/hg38 |
| NM_001349956.1 | chr22:g.28734445delA | c.277delT | p.W93Gfs*17 | RefSeq | GRCh38/hg38 |
| XM_047441106.1 | chr22:g.28734445_28734446insTTGGGCC | c.276_277insGGCCCAA | p.W93Gfs*17 | RefSeq | GRCh38/hg38 |
| NM_007194.4 | chr22:g.28734445delA | c.277delT | p.W93Gfs*17 | RefSeq | GRCh38/hg38 |
| NM_145862.2 | chr22:g.28734445delA | c.277delT | p.W93Gfs*17 | RefSeq | GRCh38/hg38 |
| XM_047441104.1 | chr22:g.28734445_28734446insTTGGGCC | c.276_277insGGCCCAA | p.W93Gfs*17 | RefSeq | GRCh38/hg38 |
| NM_145862 | chr22:g.28734445delA | c.277delT | p.W93Gfs*17 | RefSeq | GRCh38/hg38 |
| NM_001005735 | chr22:g.28734446_28734447insCGGGCCG | c.276_277insGGCCCGC | p.W93Gfs*17 | RefSeq | GRCh38/hg38 |
| NM_001349956.2 | chr22:g.28734445delA | c.277delT | p.W93Gfs*17 | RefSeq | GRCh38/hg38 |
| XM_011529841.1 | chr22:g.28734445_28734446insTTGGGCC | c.276_277insGGCCCAA | p.W93Gfs*17 | RefSeq | GRCh38/hg38 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|